21.2.2023 | Tahko Ski Lift Pitch

Marginum – Next-generation technology for cancer surgery

Marginum is pioneering patent-pending tissue identification technologies for surgery, enabling safe and efficient monitoring of tumour tissues during operations and improving surgical performance and cost-effectiveness. The company was founded in 2020 by a team of professionals with a superior background in quantitative surgical techniques.
The first product’s idea emerged from internationally competitive research on optic tissue biomarkers at the University of Eastern Finland (UEF) and Kuopio University Hospital (KUH). The innovation enables surgeons to operate tumours more efficiently and can reduce the number of reoperations and harm caused to patients. The solution is scalable to address a global problem and suitable for both developed and emerging markets.
Derived from experimental state-of-the-art research, the products will detect tumour cells from surgical suction waste based on defined fluorescence. Surgical tissue monitoring increases tumour removal rates and patient safety by guiding surgeon’s decision-making during surgery. The innovation will result in decreased local cancer recurrence, improved patient care and diminished healthcare costs.

Marginum’s work has led to numerous technological breakthroughs and gained several academic and business awards. A catalyst for the UEF research team’s efforts was winning the Tahko Ski Lift Pitch 2022 pitching competition. In addition to the prize money and several new contacts from potential investors and business partners, Marginum was also featured at the iconic Nasdaq tower in New York Times Square, a significant milestone for the company.

We are pursuing market entry exceptionally fast – in 2024 – and work with industry-leading academic and clinical experts to ensure the safety, efficiency and clinical applicability of our technological solutions, says Samu Lehtonen, the company’s CEO.

Marginum warmly recommends the Tahko Ski Lift Pitch event to everyone interested in the start-up scene. Participation is highly encouraged especially for research teams considering commercializing their research. The event is excellent for networking with start-ups, investors and experts. Tahko skiing slopes also merit a visit on their own.
Additional information:
Samu Lehtonen
CEO, Marginum Ltd
+358 40 579 7890

The original article can be read on the Tahko Ski Lift Pitch website.


28.6.2024 | Marginum News

Marginum quality management system ISO 13485:2016 certified

The quality management system of Marginum has been assessed and certified as meeting the requirements of ISO 13485:2016 and EN ISO 13485:2016.

10.11.2023 | Marginum News

Marginum raises €1.7 million for market entry of tissue sensing technology for cancer surgery

Almaral, Nostetta Ventures, and Redstone led the investment into Finnish medical technology company Marginum, coupled with Business Finland R&D loan.

22.3.2023 | Marginum News

Marginum started clinical trials of a new technique for tumour surgery

Marginum Ltd has initiated its first-in-human clinical trials with the aspirate tissue monitor at the Kuopio University Hospital.

21.2.2023 | Tahko Ski Lift Pitch

Marginum – Next-generation technology for cancer surgery

Tahko Ski Lift Pitch winner Marginum is pioneering optic tissue monitoring with groundbreaking innovation borne from multidisciplinary UEF research.

10.10.2022 | Kuopio Chamber of Commerce

TSLP winner Marginum increases the efficiency of cancer surgery

Marginum joins Kuopio Chamber of Commerce and the Finnish Startup Community after winning Tahko Ski Lift Pitch 2022.

4.10.2022 | University of Eastern Finland

Marginum selected by University of Eastern Finland to Stage Two

Marginum has been nominated by University of Eastern Finland (UEF) to participate at Stage Two competition in Berlin.